Saint-Gobain Bioprocess Solutions Business Announces C-Flex® Production Capability in Suwa, Japan
Saint-Gobain Life Sciences today announced the addition of their Suwa, Japan manufacturing facility for the production of C-Flex® TPE tubing for use in bioprocessing. The capacity addition in Suwa is part of Saint-Gobain Life Sciences ongoing investment plan to globally expand production capacity for its products and services used throughout the bioprocessing industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005135/en/
Saint-Gobain Life Sciences C-Flex® tubing extrusion in facility clean room. (Photo: Business Wire)
“The Suwa site expansion further enhances our global manufacturing network, with a specific emphasis on supporting availability of our C-Flex® TPE tubing in Asia,” said Benjamin Le Quéré, Bioprocess Solutions business unit General Manager at Saint-Gobain Life Sciences. “With the completion of Suwa’s capability, we will have C-Flex® production capacity in five separate facilities in four countries. This is a unique capability in TPE tubing for bioprocessing and it supports our mission to provide security of supply.”
Site Location | Operational Status |
Clearwater, FL USA | Operational |
Charny, FRA | Operational |
Largo, FL USA | Operational |
Bangalore, IND | Operational |
Suwa, JPN | Planned Q4 2022 |
Hangzhou, CHN | Planned Q1 2023 |
“We have been making substantial progress on improving C-Flex® service levels and lead-times through Q2 of this year,” said Le Quéré. “The Suwa, Japan production capacity being added in Q4 and the addition of Hangzhou capacity in early 2023 will further strengthen our ability to meet the needs of the bioprocess industry.”
The C-Flex® production expansion to the Saint-Gobain facility in Suwa, Japan is part of a multi-year manufacturing strategy, increasing Bioprocess Solutions business unit production capacity around the globe, creating redundant manufacturing capabilities across Europe, North America, and Asia to support increasing customer demand.
The Saint-Gobain Suwa facility has been in operation since 1992 and employs approximately 100 employees, providing production capability to multiple businesses within the Saint-Gobain Group.
About Saint-Gobain Life Sciences
Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical, and pharmaceutical customers around the world.
Saint-Gobain Life Sciences is part of Saint-Gobain Group, a worldwide leader in light and sustainable construction, which designs, manufactures, and distributes materials and services for the construction and industrial markets.
€44.2 billion in sales in 2021
166,000 employees, located in 75 countries
Committed to achieving Carbon Neutrality by 2050
For more details on Saint-Gobain, visit: http://www.saint-gobain.com and follow us on Twitter @saintgobain.
And visit: https://www.biopharm.saint-gobain.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005135/en/
Contact information
Katy Oroszi
Saint-Gobain Life Sciences
Marketing Communications Manager
Katy.oroszi@saint-gobain.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
I-care Becomes a Unicorn23.12.2025 10:45:00 CET | Press Release
I-care announces the completion of a €20 million fundraising and refinancing operation, carried out as a round reserved for existing shareholders and employees. Based on this operation, the group's valuation reaches €1 billion, making I-care a unicorn. "Becoming a unicorn is a symbolic milestone. To achieve this, we chose to invest before reaping the rewards: we bet on AI when few believed in it, we prioritized R&D, and we built our own production unit. These choices were sometimes difficult, but they were essential to staying ahead of the game. Today, our results confirm that this strategy was the right one," explains Fabrice Brion, CEO of I-care. This fundraising round is the first step in a three-phase development plan. Following the “Eau Rouge” operation in 2022, which enabled I-care to become the world leader in predictive maintenance, the company has now set itself a clear objective: to accelerate its growth in order to increase its market share. The second phase of this plan wil
Liquid Reply Joins the Agentic AI Foundation (AAIF) to Advance Open, Trusted Agentic AI23.12.2025 10:00:00 CET | Press Release
Liquid Reply, specialising in platform engineering and cloud-native technologies within the Reply Group, today announced that it has joined the Agentic AI Foundation (AAIF). The newly established foundation was launched under the auspices of the Linux Foundation and provides a neutral, open governance framework for the development of agent-based AI systems. Members collaborate transparently to develop tools, protocols, and specifications that remain available as open-source resources for the global community. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223604862/en/ Through its membership, Liquid Reply will engage the AAIF community and actively support the establishment of open standards for the next generation of AI-powered applications. By joining the AAIF, Liquid Reply reinforces its commitment to open-source and community-driven innovation, and supports the creation of shared technical foundations for the responsi
Rajant Kinetic Mesh® Proves Subterranean Connectivity During NATO ARRC “Ex AVENGER TRIAD 25” Exercise23.12.2025 10:00:00 CET | Press Release
Rajant Corporation, the exclusive provider of peer to peer, private Kinetic Mesh® networks consisting of BreadCrumb® wireless nodes powered by InstaMesh® routing, today announced the successful completion of a subterranean communications trial during NATO Allied Rapid Reaction Corps’ (ARRC) primary exercise of the year, Ex AVENGER TRIAD 25, which was conducted in October–November 2025. During the exercise, Rajant provided the communications equipment that delivered robust underground bandwidth in a retired mine in England. The Rajant network operated as a transport-agnostic, multi-bearer networking overlay that unified disparate communication technologies into a single resilient transport fabric, integrating cleanly with existing network transports and mission systems. ARRC users and the British Army’s 22 Signal Regiment recognized the utility of the approach and identified avenues to exploit the capability further, most notably a wireless subterranean headquarters concept, while also
Spain’s CESGA Selects IQM and Telefónica to Deploy Advanced Quantum Computing Infrastructure23.12.2025 09:53:00 CET | Press Release
IQM Quantum Computers, the global leader in deployed, on-premises computers, and Telefónica, a global telecommunications provider, have joined forces to sign a purchase agreement with the Galician Supercomputing Center (CESGA) to install two full-stack quantum computers in Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223742835/en/ Spain’s CESGA selects IQM and Telefónica to deploy advanced quantum computing infrastructure Under the agreement, IQM will deliver and install a 54-qubit IQM Radiance, designed for integration into high-performance computing centres, together with a 5-qubit IQM Spark system dedicated to education. The systems are scheduled for delivery by June 2026. The deployment will expand CESGA’s advanced computing capabilities and strengthen its role as a key national and European research infrastructure. The systems will be used by the scientific community and made accessible to leading companies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom